Navigation Links
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Date:9/17/2007

-MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius-

CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Radius Health ("Radius") announced today that it has granted Novartis (NYSE: NVS) an option to obtain an exclusive worldwide license (except Japan) to develop and commercialize all formulations of BA058, Radius' osteoporosis drug candidate. BA058 is a proprietary analog of hPTHrP (human parathyroid hormone-related protein) currently in Phase II development by Radius. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. has purchased $10 million of Series C preferred stock of Radius.

In the event that Novartis exercises the option to license BA058, Novartis would assume the global clinical development, manufacturing, and marketing of BA058 and all associated costs. Radius would receive payments on the option exercise and on successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million, part of which will be paid to Ipsen (Euronext: FR0010259150; IPN), from which Radius licensed BA058 in 2005. In addition, Radius would be eligible to receive royalties on product sales and has retained the option to co-commercialize BA058 in the United States. Additional terms were not disclosed.

"It was our stated intention to partner BA058 prior to commencing Phase III development, as this offers the best opportunity to maximize its value potential for Radius while expediting its development for the patients who need it," said C. Richard Lyttle, Ph.D., President and CEO of Radius. "Through this innovative option arrangement, we have put in place an early mechanism to partner BA058 with Novartis, a global l
'/>"/>

SOURCE Radius
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. State to offer $850K in high-tech training grants
2. Grants worth $800,000 help BellBrook Labs develop products
3. Venture-backed firms could become eligible for federal SBIR grants
4. Mithridion wins grants for Alzheimers research
5. NASDAQ grants Merge more time for compliance
6. Morgridge seed grants attract over 220 proposals
7. Medical College researchers win federal grants
8. NSF grants bolster integrative graduate study at UW-Madison
9. Three state businesses receive technology grants
10. SBC Foundation awards technology grants in Wisconsin
11. Visonex plans to expand with state grants, loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... world market for antithrombotic drugs will reach $22.4bn in ... Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 ... purpose of that investigation is to provide forecasts and ... a business information publisher and consultancy in ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular ... William S. Marth , AMRI,s President and Chief ... Merrill Lynch 2015 Health Care Conference on Wednesday, May ... live audio webcast of the presentation can be accessed ... The webcast will be archived for ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , Ph.D., ... an overview and update on the company,s business at the ... Boston, Massachusetts . The presentation ... PM Eastern Time, and can be accessed via a live ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... 2011 Bio-Research Products announced today that it is adding ... its product line. The new Glutathione Reductase offers customers a ... liquid (#801) GR enzyme. Both versions are free of ammonium ... IU/mg protein and an enzyme activity of 300 IU/mL. ...
... Inc. (OTCBB: UGNE), a leader in ... announced that Ashleigh Palmer, President and Chief Executive Officer, ... Annual Oppenheimer Healthcare Conference being held in New York ... 4:10 p.m. ET on Tuesday, December 13, 2011. ...
...  Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company ... for the treatment of autoimmune diseases and cancer, ... the Company,s President, Chief Executive Officer and Director, ... Conference on Wednesday, December 14, 2011 at 10:30 ...
Cached Biology Technology:Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011 2Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference 2
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... essential nutrient and a pollutant, a byproduct of fossil ... benefit and a hazard, depending on form, location, and ... around the planet, say sixteen scientists in the latest ... "Excess Nitrogen in the U.S. Environment: Trends, Risks, and ...
... simple experiment, University of Illinois chemists have debunked a ... by chemistry professor and Howard Hughes Medical Institute early ... top drug for treating systemic fungal infections works by ... physiology, a finding that could change the direction of ...
... sex of a fetus until after 30 weeks of pregnancy ... groups in Canada and the United States, states an editorial ... Female feticide that is, choosing to abort female ... issue in several Asian countries including India, China, Korea and ...
Cached Biology News:Solutions for a nitrogen-soaked world 2Powerful drug's surprising, simple method could lead to better treatments 2Powerful drug's surprising, simple method could lead to better treatments 3Female feticide in Canada requires action 2